Patient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice Guide
Authors:
- Jungsil RoJRJungsil Ro
- Yoon Sim YapYYYoon Sim Yap
- Asian Working Group for Eribulin Clinical GuideAGAsian Working Group for Eribulin Clinical Guide
Open Access
- 1 January 2016
- journal article
- review article
- Published by XMLink in Journal of Breast Cancer
- Vol. 19 (1) , 8-17
Abstract
Ro J, et al. J Breast Cancer. 2016 Mar;19(1):8-17. https://doi.org/10.4048/jbc.2016.19.1.8Keywords
Funding Information
- Eisai
This publication has 56 references indexed in Scilit:
- Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancerBMC Cancer, 2012
- The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findingsAnnals of Oncology, 2012
- Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline UpdateJournal of Clinical Oncology, 2011
- Eribulin mesylate in patients with refractory cancers: a Phase I studyInvestigational New Drugs, 2011
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised studyThe Lancet, 2011
- 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumoursEuropean Journal of Cancer, 2011
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- Platinum neurotoxicity pharmacogeneticsMolecular Cancer Therapeutics, 2009
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMolecular Cancer Therapeutics, 2008
- Is breast cancer survival improving?Cancer, 2003